Shruti Jain
Doctoral researcher
shrjai@utu.fi +358 29 450 4599 +358 50 573 8984 Kiinamyllynkatu 10 Turku ORCID identifier: https://orcid.org/0000-0003-0748-6050 |
Diagnostics; immunoassays; point-of-care testing; assay optimization; clinical validation; clinical verification; analytical techniques; biomarkers; tumor markers; extracellular vesicle (EV) diagnostics; clinical chemistry; laboratory medicine; statistical analysis, SPSS, Origin, JMP, R programming; science communication
Early Cancer Diagnostics group, FICAN West Cancer Centre, InFLAMES Flagship
I am a Doctoral researcher in the Doctoral Programme in Technology. I have a background in biotechnology and biochemistry. I am pursuing my PhD under the supervision of Prof. Kim Pettersson, Dr. Janne Leivo and Dr. Kamlesh Gidwani.
Cancer is largely asymptomatic in early stages and the mortality increases with late detection. I look at glycosylation changes in cancer to identify new biomarkers that can be used as diagnostic targets. We have a highly sensitive and fluoresent nanoparticle based technology that we use to develop diagnostic assays for early cancer detection. I have developed an ovarian cancer diagnostic test that shows improved performance in postmenopausal women and in early stage cases compared to conventional assays. This test is now in the commercialization phase with a local diagnostic Turku based company. During my PhD, I've also worked on identifying novel biomarkers for lung cancer diagnosis, that we are now in the process of patenting.
- MUC1 and glycan probing of CA19-9 captured biomarkers from cyst fluids and serum provides enhanced recognition of ovarian cancer (2025)
- Scientific Reports
(A1 Refereed original research article in a scientific journal) - In the Company of Giants: GYSS 2024 and the Nobel Laureate Experience (2024)
- InFLAMES Flagship Blog
(E1 Popularised blog post) - Novel circulatory biomarkers for ovarian cancer diagnosis: Nanoparticle based glycovariant assays (2024) Jain, Shruti
(G5 Article dissertation ) - Aberrant glycosylation of α3 integrins as diagnostic markers in epithelial ovarian cancer (2023)
- Clinica Chimica Acta
(A1 Refereed original research article in a scientific journal) - Diagnostic potential of nanoparticle aided assays for MUC16 and MUC1 glycovariants in ovarian cancer (2022)
- International Journal of Cancer
(A1 Refereed original research article in a scientific journal) - A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer (2020)
- Gynecologic Oncology
(A1 Refereed original research article in a scientific journal)